世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

バイオバンク市場規模、シェア、動向分析レポート:製品別(LIMS、バイオバンキング機器)、生物試料の種類別(臓器、幹細胞)、バイオバンクの種類別(リアル、バーチャル)、サービス別、用途別、地域別、セグメント別予測、2024年~2030年


Biobank Market Size, Share & Trends Analysis Report By Product (LIMS, Biobanking Equipment), By Biospecimen Type (Organs, Stem Cells), By Biobank Type (Real, Virtual), By Service, By Application, By Region, And Segment Forecasts, 2024 - 2030

バイオバンク市場の成長と動向 Grand View Research, Inc.の最新レポートによると、世界のバイオバンク市場規模は2030年までに1,369億1,000万米ドルに達し、予測期間中のCAGRは8.8%を記録すると予測されている... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Grand View Research
グランドビューリサーチ
2023年12月28日 US$5,950
シングルユーザライセンス(印刷不可)
ライセンス・価格情報
注文方法はこちら
185 英語

1~3営業日


 

サマリー

バイオバンク市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のバイオバンク市場規模は2030年までに1,369億1,000万米ドルに達し、予測期間中のCAGRは8.8%を記録すると予測されている。バイオバンクは、NGSなどの新技術の導入やゲノム医療への注目の高まりとともに進化し続けている。創薬、診断、その他を含む複数の領域に対応するために複数の種類の生物試料の利用が可能であることが、バイオバンクの多様化を加速し、市場を牽引している。生物試料の質は、疾患検査や前臨床・臨床研究に大きな影響を与える。規制機関は、サンプルの効果的な管理のためのガイドラインを確立することで、バイオバンク・サービスの採用に拍車をかける重要な役割を果たしている。

例えば、米国疾病予防管理センター(CDC)は、COVID-19サンプルの取り扱い中の人体への危険を最小限に抑えるためのガイドラインを発表した。これは他のバイオリポジトリのモデルとなっている。さらに、COVID-19に関連する研究および臨床試験の数が増加しているため、近い将来、高品質の生物試料の需要が大幅に増加し、市場の成長につながると予想される。さらに、集団ベースのコホート研究は、実際の血清有病率を推定するためにバイオレポジトリによって促進される。Health Catalyst, Inc.は、そのTouchstoneプラットフォームを通じて、COVID-19の洞察に関連する全国データを提供している。このような要因がこの分野の収益に貢献すると予想される。

BioResource」は2021年10月、ヘクサムに本拠を置くヘルスケア新興企業で、珍しい形態の癌の研究を改善することに専念するRareCan社によって創設された。BioResourceは、がん患者の手術後に採取されたサンプルを保持し、病気の治療、予防、特定に利用できる世界中の研究者がアクセスできるようにする。2021年12月、ニューカッスル大学はヒト血液サンプルとヒト組織提供の新しいコレクションを導入した。英国バイオバンクは、循環メタボロミクスバイオマーカーの範囲を測定する研究から得られた新鮮なデータをデータベースに追加したと発表した。血液バイオマーカー技術を専門とするフィンランドの企業ナイチンゲール・ヘルス社は、120000人の参加者を対象にこの研究を実施した。

さらに、米国ではCOVID-19の症例数が多く、研究開発プログラムの増加が新たなバイオリポジトリの設立につながっており、北米の収益を牽引している。アジア太平洋地域では、アジア諸国における医薬品と臨床研究の領域が拡大し続けているため、市場は最も速い成長を記録すると予想されている。主要企業は、世界的な流通業者との提携、他企業の合併・買収、研究コミュニティとの戦略的提携などにより、世界的なリーチの拡大に取り組んでいる。

バイオバンク市場レポートハイライト

- バイオバンク機器分野は、バイオリポジトリ数の増加と機器の高コストが相まって、2023年に最大の売上シェアを占めた。

- バイオバンキングおよびリポジトリサービス分野は、これらのサービスの普及率の高さ、精密医療や疾患特異的研究の開発におけるバイオサンプルの保存ニーズの高まりにより、2023年に最大の売上シェアを占めた。

- ヒト組織は臨床研究で最も保存されているサンプルであるため、このサンプルタイプが市場で優位を占めている。

- 生物医学研究のための希少疾患データの必要性と3D生物試料の需要の増加により、バーチャルバイオバンクの分野が予測期間中に最も速いCAGRを示すと予想される。

- がん治療における細胞療法の人気の高まりにより、2023年に最大の売上シェアを占めたのは治療用途分野であった。

- 複数の製薬/バイオテクノロジー企業が、臨床試験や細胞療法の開発を支援するためにプライベートバンクを設立しており、このセグメントの収益成長をもたらしている。

ページTOPに戻る


目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Service
1.2.3. Biospecimen Type
1.2.4. Biobanks Type
1.2.5. Application
1.2.6. Regional scope
1.2.7. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Service outlook
2.2.3. Biospecimen type outlook
2.2.4. Biobanks type outlook
2.2.5. Application outlook
2.2.6. Regional outlook
2.3. Competitive Insights
Chapter 3. Biobanks Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Continuous increase in COVID-19 cases along with capacity expansion
3.2.1.2. Increased focus on precision medicine and genetic testing
3.2.1.3. Changes in biobanking operations
3.2.1.4. Increase in the number of clinical trials globally
3.2.1.5. Growing industry and research collaborations
3.2.1.6. Technology advancement and automation
3.2.2. Market restraint analysis
3.2.2.1. Disruptions in supply chain management due to COVID-19
3.2.2.2. Challenges in sharing biobanking data & limited access to biospecimens
3.2.2.3. Sustainability challenges for biobanks
3.2.2.4. Other challenges in biobanking specimens for research
3.3. Biobanks Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Biobanks Market: Product Estimates & Trend Analysis
4.1. Product Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Biobanks Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Biobank Equipment
4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.2. Temperature Control Systems
4.4.1.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.2.2. Freezers & Refrigerators
4.4.1.2.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.2.3. Cryogenic Storage Systems
4.4.1.2.4. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.2.5. Thawing Equipment
4.4.1.2.6. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.3. Incubators & Centrifuges
4.4.1.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.4. Alarms & Monitoring Systems
4.4.1.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.5. Accessories & Other Equipment
4.4.1.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2. Biobanking Consumables
4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.3. Laboratory Information Management Systems
4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Biobanks Market: Service Estimates & Trend Analysis
5.1. Service Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Biobanks Market by Service Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Biobanking & repository
5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2. Lab processing
5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.3. Qualification/ Validation
5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.4. Cold Chain Logistics
5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.5. Other Services
5.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Biobanks Market: Biospecimen Type Estimates & Trend Analysis
6.1. Biospecimen Type Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Biobanks Market by Biospecimen Type Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Human Tissues
6.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.2. Human Organs
6.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3. Stem Cells
6.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3.2. Adult Stem Cells
6.4.3.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3.3. Embryonic Stem Cells
6.4.3.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3.4. IPS Cells
6.4.3.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3.5. Other Stem Cells
6.4.3.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.4. Other biospecimens
6.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Biobanks Market: Biobanks Type Estimates & Trend Analysis
7.1. Biobanks Type Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. Global Biobanks Market by Biobanks Type Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Physical/Real biobanks
7.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.1.2. Tissue Biobanks
7.4.1.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.1.3. Population based biobanks
7.4.1.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.1.4. Genetic (DNA/RNA)
7.4.1.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.1.5. Disease based biobanks
7.4.1.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.2. Virtual biobanks
7.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Biobanks Market: Application Estimates & Trend Analysis
8.1. Application Market Share, 2023 & 2030
8.2. Segment Dashboard
8.3. Global Biobanks Market by Application Outlook
8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
8.4.1. Therapeutics
8.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.2. Drug discovery & clinical research
8.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.3. Clinical Diagnostics
8.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.4. Other Applications
8.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 9. Biobanks Market: Regional Estimates & Trend Analysis
9.1. Regional Market Share Analysis, 2023 & 2030
9.2. Regional Market Dashboard
9.3. Global Regional Market Snapshot
9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
9.5. North America
9.5.1. U.S.
9.5.1.1. Key country dynamics
9.5.1.2. Regulatory framework/reimbursement structure
9.5.1.3. Competitive scenario
9.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
9.5.2. Canada
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework/reimbursement structure
9.5.2.3. Competitive scenario
9.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
9.6. Europe
9.6.1. UK
9.6.1.1. Key country dynamics
9.6.1.2. Regulatory framework/reimbursement structure
9.6.1.3. Competitive scenario
9.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.2. Germany
9.6.2.1. Key country dynamics
9.6.2.2. Regulatory framework/reimbursement structure
9.6.2.3. Competitive scenario
9.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.3. France
9.6.3.1. Key country dynamics
9.6.3.2. Regulatory framework/reimbursement structure
9.6.3.3. Competitive scenario
9.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.4. Italy
9.6.4.1. Key country dynamics
9.6.4.2. Regulatory framework/reimbursement structure
9.6.4.3. Competitive scenario
9.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.5. Spain
9.6.5.1. Key country dynamics
9.6.5.2. Regulatory framework/reimbursement structure
9.6.5.3. Competitive scenario
9.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.6. Norway
9.6.6.1. Key country dynamics
9.6.6.2. Regulatory framework/reimbursement structure
9.6.6.3. Competitive scenario
9.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.7. Sweden
9.6.7.1. Key country dynamics
9.6.7.2. Regulatory framework/reimbursement structure
9.6.7.3. Competitive scenario
9.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.8. Denmark
9.6.8.1. Key country dynamics
9.6.8.2. Regulatory framework/reimbursement structure
9.6.8.3. Competitive scenario
9.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
9.7. Asia Pacific
9.7.1. Japan
9.7.1.1. Key country dynamics
9.7.1.2. Regulatory framework/reimbursement structure
9.7.1.3. Competitive scenario
9.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.2. China
9.7.2.1. Key country dynamics
9.7.2.2. Regulatory framework/reimbursement structure
9.7.2.3. Competitive scenario
9.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.3. India
9.7.3.1. Key country dynamics
9.7.3.2. Regulatory framework/reimbursement structure
9.7.3.3. Competitive scenario
9.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.4. Australia
9.7.4.1. Key country dynamics
9.7.4.2. Regulatory framework/reimbursement structure
9.7.4.3. Competitive scenario
9.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.5. South Korea
9.7.5.1. Key country dynamics
9.7.5.2. Regulatory framework/reimbursement structure
9.7.5.3. Competitive scenario
9.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.6. Thailand
9.7.6.1. Key country dynamics
9.7.6.2. Regulatory framework/reimbursement structure
9.7.6.3. Competitive scenario
9.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
9.8. Latin America
9.8.1. Brazil
9.8.1.1. Key country dynamics
9.8.1.2. Regulatory framework/reimbursement structure
9.8.1.3. Competitive scenario
9.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
9.8.2. Mexico
9.8.2.1. Key country dynamics
9.8.2.2. Regulatory framework/reimbursement structure
9.8.2.3. Competitive scenario
9.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
9.8.3. Argentina
9.8.3.1. Key country dynamics
9.8.3.2. Regulatory framework/reimbursement structure
9.8.3.3. Competitive scenario
9.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
9.9. MEA
9.9.1. South Africa
9.9.1.1. Key country dynamics
9.9.1.2. Regulatory framework/reimbursement structure
9.9.1.3. Competitive scenario
9.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
9.9.2. Saudi Arabia
9.9.2.1. Key country dynamics
9.9.2.2. Regulatory framework/reimbursement structure
9.9.2.3. Competitive scenario
9.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
9.9.3. UAE
9.9.3.1. Key country dynamics
9.9.3.2. Regulatory framework/reimbursement structure
9.9.3.3. Competitive scenario
9.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
9.9.4. Kuwait
9.9.4.1. Key country dynamics
9.9.4.2. Regulatory framework/reimbursement structure
9.9.4.3. Competitive scenario
9.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Company/Competition Categorization
10.3. Vendor Landscape
10.3.1. List of key distributors and channel partners
10.3.2. Key customers
10.3.3. Key company market share analysis, 2023
10.3.4. Thermo Fisher Scientific Inc.
10.3.4.1. Company overview
10.3.4.2. Financial performance
10.3.4.3. Product benchmarking
10.3.4.4. Strategic initiatives
10.3.5. Merck KGaA
10.3.5.1. Company overview
10.3.5.2. Financial performance
10.3.5.3. Product benchmarking
10.3.5.4. Strategic initiatives
10.3.6. Qiagen
10.3.6.1. Company overview
10.3.6.2. Financial performance
10.3.6.3. Product benchmarking
10.3.6.4. Strategic initiatives
10.3.7. Hamilton Company
10.3.7.1. Company overview
10.3.7.2. Financial performance
10.3.7.3. Product benchmarking
10.3.7.4. Strategic initiatives
10.3.8. Tecan Trading AG
10.3.8.1. Company overview
10.3.8.2. Financial performance
10.3.8.3. Product benchmarking
10.3.8.4. Strategic initiatives
10.3.9. Danaher Corporation
10.3.9.1. Company overview
10.3.9.2. Financial performance
10.3.9.3. Product benchmarking
10.3.9.4. Strategic initiatives
10.3.10. Becton, Dickinson, and Company (BD)
10.3.10.1. Company overview
10.3.10.2. Financial performance
10.3.10.3. Product benchmarking
10.3.10.4. Strategic initiatives
10.3.11. Biocision, LLC.
10.3.11.1. Company overview
10.3.11.2. Financial performance
10.3.11.3. Product benchmarking
10.3.11.4. Strategic initiatives
10.3.12. Taylor-Wharton
10.3.12.1. Company overview
10.3.12.2. Financial performance
10.3.12.3. Product benchmarking
10.3.12.4. Strategic initiatives
10.3.13. Charles River Laboratories
10.3.13.1. Company overview
10.3.13.2. Financial performance
10.3.13.3. Product benchmarking
10.3.13.4. Strategic initiatives
10.3.14. Lonza
10.3.14.1. Company overview
10.3.14.2. Financial performance
10.3.14.3. Product benchmarking
10.3.14.4. Strategic initiatives
10.3.15. Stemcell Technologies
10.3.15.1. Company overview
10.3.15.2. Financial performance
10.3.15.3. Product benchmarking
10.3.15.4. Strategic initiatives
10.3.16. Biovault Family
10.3.16.1. Company overview
10.3.16.2. Financial performance
10.3.16.3. Product benchmarking
10.3.16.4. Strategic initiatives
10.3.17. Promocell Gmbh
10.3.17.1. Company overview
10.3.17.2. Financial performance
10.3.17.3. Product benchmarking
10.3.17.4. Strategic initiatives
10.3.18. Precision Cellular Storage Ltd. (Virgin Health Bank)
10.3.18.1. Company overview
10.3.18.2. Financial performance
10.3.18.3. Product benchmarking
10.3.18.4. Strategic initiatives

 

ページTOPに戻る


 

Summary

Biobanks Market Growth & Trends

The global biobanks market size is expected to reach USD 136.91 billion by 2030, registering a CAGR of 8.8% during the forecast period, according to a new report by Grand View Research, Inc. Biobanks continue to evolve with the introduction of new technologies, such as NGS, and increased focus on genomic medicine. The availability of several types of biospecimens to cater to multiple domains including drug discovery, diagnostics, and others has accelerated the diversification of biorepositories, thereby driving the market. The quality of biospecimens can significantly influence disease testing as well as preclinical and clinical research. Regulatory agencies have played a vital role in spurring the adoption of biobanking services by establishing guidelines for the effective management of samples.

For instance, the U.S. Centers for Disease Control and Prevention (CDC) released guidelines to minimize human hazards while handling COVID-19 samples. This serves as a model for other biorepositories. Furthermore, as the number of research studies and clinical trials related to COVID-19 is increasing, the demand for high-quality biospecimens is expected to significantly increase in the near future, leading to market growth. In addition, population-based cohort studies are facilitated by biorepositories to estimate the actual seroprevalence. Health Catalyst, Inc., through its Touchstone platform, provides national data related to COVID-19 insights. Such factors are anticipated to contribute to the revenue flow in this space.

The ‘BioResource’ was created in October 2021 by RareCan, a Hexham-based healthcare start-up dedicated to improving studies into the uncommon forms of cancer. BioResource will retain samples taken after surgery from cancer patients and make them accessible to researchers across the globe who can use them to cure, prevent, and identify the disease. In December 2021, Newcastle University introduced a new collection of human blood samples and donated human tissue, which could transform efforts to cure rare cancers. The U.K. Biobank has announced that fresh data from a study measuring the range of circulatory metabolomics biomarkers has been added to its database. Nightingale Health, a Finnish business specializing in blood biomarker technologies, conducted the study with 120000 participants.

North America dominated the market with its wide network of centers for biosample storage in the U.S. Moreover, a high number of COVID-19 cases in the U.S. and increased R&D programs have resulted in the establishment of new biorepositories, thereby driving revenue in North America. In Asia Pacific, the market is anticipated to register the fastest growth owing to the ever-expanding pharmaceuticals and clinical research domain across Asian countries. The key players are engaged in expanding their global reach by partnering with global distributors, mergers, and acquisitions of other players, and entering a strategic alliance with research communities.

Biobanks Market Report Highlights

• The biobanking equipment segment accounted for the maximum revenue share in 2023 owing to the high cost of instruments coupled with an increase in the number of biorepositories

• The biobanking and repository services segment accounted for the largest revenue share in 2023 due to the higher penetration of these services and the increased need for the preservation of biosamples for developing precision medicine and disease-specific research

• Human tissues are the most stored sample for clinical research, resulting in the dominance of this sample type in the market

• The virtual biobanks segment is anticipated to witness the fastest CAGR during the forecast period owing to the growing demand for 3D biospecimens coupled with the need for rare disease data for biomedical research

• The therapeutics application segment accounted for the largest revenue share in 2023 owing to the growing popularity of cell therapies for cancer treatment

• Several pharma/biotech companies have established their private banks to support clinical trials and the development of cell therapies, resulting in revenue growth in this segment.



ページTOPに戻る


Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Service
1.2.3. Biospecimen Type
1.2.4. Biobanks Type
1.2.5. Application
1.2.6. Regional scope
1.2.7. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Service outlook
2.2.3. Biospecimen type outlook
2.2.4. Biobanks type outlook
2.2.5. Application outlook
2.2.6. Regional outlook
2.3. Competitive Insights
Chapter 3. Biobanks Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Continuous increase in COVID-19 cases along with capacity expansion
3.2.1.2. Increased focus on precision medicine and genetic testing
3.2.1.3. Changes in biobanking operations
3.2.1.4. Increase in the number of clinical trials globally
3.2.1.5. Growing industry and research collaborations
3.2.1.6. Technology advancement and automation
3.2.2. Market restraint analysis
3.2.2.1. Disruptions in supply chain management due to COVID-19
3.2.2.2. Challenges in sharing biobanking data & limited access to biospecimens
3.2.2.3. Sustainability challenges for biobanks
3.2.2.4. Other challenges in biobanking specimens for research
3.3. Biobanks Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Biobanks Market: Product Estimates & Trend Analysis
4.1. Product Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Biobanks Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Biobank Equipment
4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.2. Temperature Control Systems
4.4.1.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.2.2. Freezers & Refrigerators
4.4.1.2.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.2.3. Cryogenic Storage Systems
4.4.1.2.4. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.2.5. Thawing Equipment
4.4.1.2.6. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.3. Incubators & Centrifuges
4.4.1.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.4. Alarms & Monitoring Systems
4.4.1.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.5. Accessories & Other Equipment
4.4.1.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2. Biobanking Consumables
4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.3. Laboratory Information Management Systems
4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Biobanks Market: Service Estimates & Trend Analysis
5.1. Service Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Biobanks Market by Service Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Biobanking & repository
5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2. Lab processing
5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.3. Qualification/ Validation
5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.4. Cold Chain Logistics
5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.5. Other Services
5.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Biobanks Market: Biospecimen Type Estimates & Trend Analysis
6.1. Biospecimen Type Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Biobanks Market by Biospecimen Type Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Human Tissues
6.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.2. Human Organs
6.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3. Stem Cells
6.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3.2. Adult Stem Cells
6.4.3.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3.3. Embryonic Stem Cells
6.4.3.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3.4. IPS Cells
6.4.3.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3.5. Other Stem Cells
6.4.3.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.4. Other biospecimens
6.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Biobanks Market: Biobanks Type Estimates & Trend Analysis
7.1. Biobanks Type Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. Global Biobanks Market by Biobanks Type Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Physical/Real biobanks
7.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.1.2. Tissue Biobanks
7.4.1.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.1.3. Population based biobanks
7.4.1.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.1.4. Genetic (DNA/RNA)
7.4.1.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.1.5. Disease based biobanks
7.4.1.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.2. Virtual biobanks
7.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Biobanks Market: Application Estimates & Trend Analysis
8.1. Application Market Share, 2023 & 2030
8.2. Segment Dashboard
8.3. Global Biobanks Market by Application Outlook
8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
8.4.1. Therapeutics
8.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.2. Drug discovery & clinical research
8.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.3. Clinical Diagnostics
8.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.4. Other Applications
8.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 9. Biobanks Market: Regional Estimates & Trend Analysis
9.1. Regional Market Share Analysis, 2023 & 2030
9.2. Regional Market Dashboard
9.3. Global Regional Market Snapshot
9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
9.5. North America
9.5.1. U.S.
9.5.1.1. Key country dynamics
9.5.1.2. Regulatory framework/reimbursement structure
9.5.1.3. Competitive scenario
9.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
9.5.2. Canada
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework/reimbursement structure
9.5.2.3. Competitive scenario
9.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
9.6. Europe
9.6.1. UK
9.6.1.1. Key country dynamics
9.6.1.2. Regulatory framework/reimbursement structure
9.6.1.3. Competitive scenario
9.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.2. Germany
9.6.2.1. Key country dynamics
9.6.2.2. Regulatory framework/reimbursement structure
9.6.2.3. Competitive scenario
9.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.3. France
9.6.3.1. Key country dynamics
9.6.3.2. Regulatory framework/reimbursement structure
9.6.3.3. Competitive scenario
9.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.4. Italy
9.6.4.1. Key country dynamics
9.6.4.2. Regulatory framework/reimbursement structure
9.6.4.3. Competitive scenario
9.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.5. Spain
9.6.5.1. Key country dynamics
9.6.5.2. Regulatory framework/reimbursement structure
9.6.5.3. Competitive scenario
9.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.6. Norway
9.6.6.1. Key country dynamics
9.6.6.2. Regulatory framework/reimbursement structure
9.6.6.3. Competitive scenario
9.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.7. Sweden
9.6.7.1. Key country dynamics
9.6.7.2. Regulatory framework/reimbursement structure
9.6.7.3. Competitive scenario
9.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.8. Denmark
9.6.8.1. Key country dynamics
9.6.8.2. Regulatory framework/reimbursement structure
9.6.8.3. Competitive scenario
9.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
9.7. Asia Pacific
9.7.1. Japan
9.7.1.1. Key country dynamics
9.7.1.2. Regulatory framework/reimbursement structure
9.7.1.3. Competitive scenario
9.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.2. China
9.7.2.1. Key country dynamics
9.7.2.2. Regulatory framework/reimbursement structure
9.7.2.3. Competitive scenario
9.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.3. India
9.7.3.1. Key country dynamics
9.7.3.2. Regulatory framework/reimbursement structure
9.7.3.3. Competitive scenario
9.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.4. Australia
9.7.4.1. Key country dynamics
9.7.4.2. Regulatory framework/reimbursement structure
9.7.4.3. Competitive scenario
9.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.5. South Korea
9.7.5.1. Key country dynamics
9.7.5.2. Regulatory framework/reimbursement structure
9.7.5.3. Competitive scenario
9.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.6. Thailand
9.7.6.1. Key country dynamics
9.7.6.2. Regulatory framework/reimbursement structure
9.7.6.3. Competitive scenario
9.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
9.8. Latin America
9.8.1. Brazil
9.8.1.1. Key country dynamics
9.8.1.2. Regulatory framework/reimbursement structure
9.8.1.3. Competitive scenario
9.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
9.8.2. Mexico
9.8.2.1. Key country dynamics
9.8.2.2. Regulatory framework/reimbursement structure
9.8.2.3. Competitive scenario
9.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
9.8.3. Argentina
9.8.3.1. Key country dynamics
9.8.3.2. Regulatory framework/reimbursement structure
9.8.3.3. Competitive scenario
9.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
9.9. MEA
9.9.1. South Africa
9.9.1.1. Key country dynamics
9.9.1.2. Regulatory framework/reimbursement structure
9.9.1.3. Competitive scenario
9.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
9.9.2. Saudi Arabia
9.9.2.1. Key country dynamics
9.9.2.2. Regulatory framework/reimbursement structure
9.9.2.3. Competitive scenario
9.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
9.9.3. UAE
9.9.3.1. Key country dynamics
9.9.3.2. Regulatory framework/reimbursement structure
9.9.3.3. Competitive scenario
9.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
9.9.4. Kuwait
9.9.4.1. Key country dynamics
9.9.4.2. Regulatory framework/reimbursement structure
9.9.4.3. Competitive scenario
9.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Company/Competition Categorization
10.3. Vendor Landscape
10.3.1. List of key distributors and channel partners
10.3.2. Key customers
10.3.3. Key company market share analysis, 2023
10.3.4. Thermo Fisher Scientific Inc.
10.3.4.1. Company overview
10.3.4.2. Financial performance
10.3.4.3. Product benchmarking
10.3.4.4. Strategic initiatives
10.3.5. Merck KGaA
10.3.5.1. Company overview
10.3.5.2. Financial performance
10.3.5.3. Product benchmarking
10.3.5.4. Strategic initiatives
10.3.6. Qiagen
10.3.6.1. Company overview
10.3.6.2. Financial performance
10.3.6.3. Product benchmarking
10.3.6.4. Strategic initiatives
10.3.7. Hamilton Company
10.3.7.1. Company overview
10.3.7.2. Financial performance
10.3.7.3. Product benchmarking
10.3.7.4. Strategic initiatives
10.3.8. Tecan Trading AG
10.3.8.1. Company overview
10.3.8.2. Financial performance
10.3.8.3. Product benchmarking
10.3.8.4. Strategic initiatives
10.3.9. Danaher Corporation
10.3.9.1. Company overview
10.3.9.2. Financial performance
10.3.9.3. Product benchmarking
10.3.9.4. Strategic initiatives
10.3.10. Becton, Dickinson, and Company (BD)
10.3.10.1. Company overview
10.3.10.2. Financial performance
10.3.10.3. Product benchmarking
10.3.10.4. Strategic initiatives
10.3.11. Biocision, LLC.
10.3.11.1. Company overview
10.3.11.2. Financial performance
10.3.11.3. Product benchmarking
10.3.11.4. Strategic initiatives
10.3.12. Taylor-Wharton
10.3.12.1. Company overview
10.3.12.2. Financial performance
10.3.12.3. Product benchmarking
10.3.12.4. Strategic initiatives
10.3.13. Charles River Laboratories
10.3.13.1. Company overview
10.3.13.2. Financial performance
10.3.13.3. Product benchmarking
10.3.13.4. Strategic initiatives
10.3.14. Lonza
10.3.14.1. Company overview
10.3.14.2. Financial performance
10.3.14.3. Product benchmarking
10.3.14.4. Strategic initiatives
10.3.15. Stemcell Technologies
10.3.15.1. Company overview
10.3.15.2. Financial performance
10.3.15.3. Product benchmarking
10.3.15.4. Strategic initiatives
10.3.16. Biovault Family
10.3.16.1. Company overview
10.3.16.2. Financial performance
10.3.16.3. Product benchmarking
10.3.16.4. Strategic initiatives
10.3.17. Promocell Gmbh
10.3.17.1. Company overview
10.3.17.2. Financial performance
10.3.17.3. Product benchmarking
10.3.17.4. Strategic initiatives
10.3.18. Precision Cellular Storage Ltd. (Virgin Health Bank)
10.3.18.1. Company overview
10.3.18.2. Financial performance
10.3.18.3. Product benchmarking
10.3.18.4. Strategic initiatives

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります


よくあるご質問


Grand View Research社はどのような調査会社ですか?


グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/07 10:27

155.63 円

167.26 円

203.27 円

ページTOPに戻る